27 research outputs found

    Pentadecapeptide BPC 157 Counteracts Hypertension and Compromised Optic Disc Circulation and Following Atrophy in Rats Subjected to High Fructose Diet

    Get PDF
    INTRODUCTION We sought to determine whether stable gastric pentadecapeptide BPC 157 in rats subjected to a high fructose diet counteracts hypertension and compromised optic disc circulation and following atrophy. METHODS: Rats were put on a high fructose (80%) diet during a 1 month period. The treated group received BPC 157 in drinking water (10 ng/kg/rat/day). Their blood pressure was regularly measured, and they were subjected to ocular fundus examination. RESULTS At the end of the 1 month period, in control rats, with a mean blood pressure of 146 mmHg, we observed a pale optic disc with well-defined outer borders. In addition, the excavation noticed suggests compromised optic disc circulation and atrophy. Very thin arteries and thick hyperemic veins appeared, resulting in an arterial/vein diameter ratio of about 1/4. An abnormal red reflex and reduced brightness from the choroid suggests a decreased blood flow and choroidal blood filling. Contrarily, in the treated group of rats, who presented with a mean blood pressure of about 132 mmHg, all these changes were significantly attenuated. The optic disc appeared more vivid and healthier with less compromised circulation, and the arterial/vein diameter ratio was about 3/4. The choroid in rats drinking BPC 157 was brighter and with a more pronounced shade of red. CONCLUSION BPC 157 may be considered for treating hypertension, particularly when vascular obstruction is present

    Spinal instability in rats counteracted by pentadecapeptide BPC 157

    Get PDF
    To induce spinal instability, we focused on bilateral facetectomy in rats and possible therapeutic benefit with the stable gastric pentadecapeptide BPC 157 given in the drinking water. Male Albino Wistar rats (12 weeks aged, 350-400 g b.w.), 4 rats per group, were used in the experiment. In this study, the bilateral paravertebral muscles attached to the L3ā€“L4 segment were peeled from the lumbar spine to expose the posterior bony elements. The rats then underwent complete resection of bilateral L3ā€“L4 facet joints without neural tissue injuries. After that, muscle and skin incsion were closed and animals returned to cages in pairs. The medication was administrated through drinking water (BPC 157 10 ng/kg, 0.16 ng/mL, 12 ml/rat/day), while controls received drinking water only. Next eight weeks we recorded and measured paw parameters (the lenght between left and right front and back paws) in control, treated and healthy rats. Radiological analysis was also performed. The paw parametars have shown that the front paws in the control group were approximately 35% and the back paws were 13% wider than in helathy rats. Contrarily, the front paws in medicated rats were only 9% and the back paws were only 4% wider than in healthy ones. Radiological assesment of rats spines acquired at 1 week or 8 weeks was conducted and BPC 157 drinking animals had higher bone density overall. BPC 157 improves damage caused by spine instability and it can be potentially used as a treatment for chronic back pain

    The effect of pentadecapeptide BPC 157 on high-fat diet induced hypertension in rat

    Get PDF
    Hyperlipidaemia, hypercholesterolaemia and hypertriglyceridaemia are known as factors that increas blood pressure and risk of cardiovascular complications. We wanted to examine effects of pentadecapeptide BPC 157 on high-fat diet induced hypertension in rats. 4 Male Winstar Albino rats (240g) 4 months old, were used in this study. 2 rats per each group were fed with fat (white bacon) for 4 weeks. Control group was given water p.o. ad libitum while BPC group was given (10ng/kg) of pentadecapeptide BPC 157 per liter solution p.o. ad libitum. Blood pressure was measured using noninvasive tail cuff method every day for 4 weeks period. Systolic blood pressure increased in both groups but increase in control groups was significantly higher then in BPC 157 threated group (CON day 0. = 158 mmHg, BPC day 0. = 155 mmHg; CON day 25. = 205 mmHg, BPC day 25. = 165 mmHg) .Drop of blood pressure in first few days can be attributed to adapting on the new food that was given to rats. Feeding rats with a high-fat diet is known to produce changes of which one of the consequence is increased blood pressure or hypertension. We proved that pentadecapeptide BPC 157 decreases systolic blood pressure induced by fat diet

    Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats

    Get PDF
    Pentadecapeptide BPC 157 demonstrates beneficial healing and anti-inflammatory effects on gastrointestinal and many extra - gastrointestinal tissues. Bile duct ligation causes inflammation and fibrotic changes in the liver. We wanted to explore effect of BPC 157 on bile duct ligation (BDL) in rats. Rats received BPC 157 perorally, in drinking water (0.16Ī¼g/ml, 0.16ng/ml,), or 10 Ī¼g/kg, 10 ng/kg intraperitoneally, first application at 30 min after surgery, last at 24h before sacrifice. Alternatively, delayed therapy, BPC 157 perorally, in drinking water (0.16Ī¼g/ml), started at the end of week 4 . Controls received simultaneously drinking water or an equal volume of saline (5ml/kg) intraperitoneally. At the end of the 2nd week, quantitative measurement of IL-1, IL-6 and TNF-Ī± has been utilized using ELISA kits and NOS-3 Western Blot Analysis was performed. For assessing cell proliferation rate antibodies of monoclonal mouse Ki-67 were used at the 2, 4, 6, 8 week of BDL. Western blot analysis of NOS-3 expression in liver tissue showed that BPC 157 decreased the expression of NOS-3 protein. At 2 weeks, BDL-rat regularly exhibited the increased TNF-Ī±, IL-6 and IL-1Ī² liver levels but these values were counteracted with the administration of BPC 157 in drinking water. Since 2nd week until the 8th week, we noted decreased LI of Ki-67. This research shows that BPC 157 decreases hepatocyte proliferative activity, counteracts increased NOSā€“3 expresion, as well as increased IL-6, TNF-Ī±, IL-1Ī² in liver tissue

    Pentadecapeptide BPC 157 therapy in rats with cysteamine induced-terminal ileitis

    Get PDF
    We introduce pentadecapeptide BPC 157 therapy in rats with cysteamine induced-terminal ileitis 1h/1month/2months. We counteracted gross hyperemia, edema, erosion, bleeding, microscopically significant loss of villous architecture, loss and shortening of villae and severe lymphocytic infiltrate. Pentadecapeptide counteracts various lesions in the whole GI-tract and free radical formation, and tested in ulcerative colitis trials and now in multiple sclerosis. Cysteamine was known to induce gastric-acid hypersecretion as a prototype of duodenal lesion. Cysteamine induced duodenal lesions after gastrectomy, and applied as an enema, ulcerative colitis in rats Cysteamine was applied in female Albino Wistar rats into the terminal ileum, 5 cm segment up to ileocecal valve, which was kept gently compressed for 1 min, and then released. Medication(BPC, or saline (controls)) was applied as an abdominal bath immediately after the end of the cysteamine application procedure, and then if rats were not sacrificed at 1 h, continuously, perorally in drinking water till the end of 1 or 2 months The hyperemia, edema, erosion and bleeding scores were summarized. Microscopically, cysteamine induced terminal ileitis presents with: submucosal congestion, significant loss of villous architecture, loss and shortening of villae and lamina propria infiltrated with mild to severe lymphocytic infiltrate, much like intraepithelial lymphocyte infiltration and some epithelial elevation from lamina propria. Better preservation of mucosal architecture appears in pentadecapeptide treated rats. There is only mild villous edema with capillary congestion and mild lymphocytic infiltrate. No epithelial elevation from lamina propria For further therapy, beneficial effect of the BPC counteracts cysteamine- terminal ileitis

    Pentadecapeptide BPC 157 Counteracts Hypertension and Compromised Optic Disc Circulation and Following Atrophy in Rats Subjected to High Fructose Diet

    Get PDF
    INTRODUCTION We sought to determine whether stable gastric pentadecapeptide BPC 157 in rats subjected to a high fructose diet counteracts hypertension and compromised optic disc circulation and following atrophy. METHODS: Rats were put on a high fructose (80%) diet during a 1 month period. The treated group received BPC 157 in drinking water (10 ng/kg/rat/day). Their blood pressure was regularly measured, and they were subjected to ocular fundus examination. RESULTS At the end of the 1 month period, in control rats, with a mean blood pressure of 146 mmHg, we observed a pale optic disc with well-defined outer borders. In addition, the excavation noticed suggests compromised optic disc circulation and atrophy. Very thin arteries and thick hyperemic veins appeared, resulting in an arterial/vein diameter ratio of about 1/4. An abnormal red reflex and reduced brightness from the choroid suggests a decreased blood flow and choroidal blood filling. Contrarily, in the treated group of rats, who presented with a mean blood pressure of about 132 mmHg, all these changes were significantly attenuated. The optic disc appeared more vivid and healthier with less compromised circulation, and the arterial/vein diameter ratio was about 3/4. The choroid in rats drinking BPC 157 was brighter and with a more pronounced shade of red. CONCLUSION BPC 157 may be considered for treating hypertension, particularly when vascular obstruction is present

    Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats

    Get PDF
    Pentadecapeptide BPC 157 demonstrates beneficial healing and anti-inflammatory effects on gastrointestinal and many extra - gastrointestinal tissues. Bile duct ligation causes inflammation and fibrotic changes in the liver. We wanted to explore effect of BPC 157 on bile duct ligation (BDL) in rats. Rats received BPC 157 perorally, in drinking water (0.16Ī¼g/ml, 0.16ng/ml,), or 10 Ī¼g/kg, 10 ng/kg intraperitoneally, first application at 30 min after surgery, last at 24h before sacrifice. Alternatively, delayed therapy, BPC 157 perorally, in drinking water (0.16Ī¼g/ml), started at the end of week 4 . Controls received simultaneously drinking water or an equal volume of saline (5ml/kg) intraperitoneally. At the end of the 2nd week, quantitative measurement of IL-1, IL-6 and TNF-Ī± has been utilized using ELISA kits and NOS-3 Western Blot Analysis was performed. For assessing cell proliferation rate antibodies of monoclonal mouse Ki-67 were used at the 2, 4, 6, 8 week of BDL. Western blot analysis of NOS-3 expression in liver tissue showed that BPC 157 decreased the expression of NOS-3 protein. At 2 weeks, BDL-rat regularly exhibited the increased TNF-Ī±, IL-6 and IL-1Ī² liver levels but these values were counteracted with the administration of BPC 157 in drinking water. Since 2nd week until the 8th week, we noted decreased LI of Ki-67. This research shows that BPC 157 decreases hepatocyte proliferative activity, counteracts increased NOSā€“3 expresion, as well as increased IL-6, TNF-Ī±, IL-1Ī² in liver tissue

    Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats

    Get PDF
    Pentadecapeptide BPC 157 demonstrates beneficial healing and anti-inflammatory effects on gastrointestinal and many extra - gastrointestinal tissues. Bile duct ligation causes inflammation and fibrotic changes in the liver. We wanted to explore effect of BPC 157 on bile duct ligation (BDL) in rats. Rats received BPC 157 perorally, in drinking water (0.16Ī¼g/ml, 0.16ng/ml,), or 10 Ī¼g/kg, 10 ng/kg intraperitoneally, first application at 30 min after surgery, last at 24h before sacrifice. Alternatively, delayed therapy, BPC 157 perorally, in drinking water (0.16Ī¼g/ml), started at the end of week 4 . Controls received simultaneously drinking water or an equal volume of saline (5ml/kg) intraperitoneally. At the end of the 2nd week, quantitative measurement of IL-1, IL-6 and TNF-Ī± has been utilized using ELISA kits and NOS-3 Western Blot Analysis was performed. For assessing cell proliferation rate antibodies of monoclonal mouse Ki-67 were used at the 2, 4, 6, 8 week of BDL. Western blot analysis of NOS-3 expression in liver tissue showed that BPC 157 decreased the expression of NOS-3 protein. At 2 weeks, BDL-rat regularly exhibited the increased TNF-Ī±, IL-6 and IL-1Ī² liver levels but these values were counteracted with the administration of BPC 157 in drinking water. Since 2nd week until the 8th week, we noted decreased LI of Ki-67. This research shows that BPC 157 decreases hepatocyte proliferative activity, counteracts increased NOSā€“3 expresion, as well as increased IL-6, TNF-Ī±, IL-1Ī² in liver tissue

    The effect of pentadecapeptide BPC 157 on high-fat diet induced hypertension in rat

    Get PDF
    Hyperlipidaemia, hypercholesterolaemia and hypertriglyceridaemia are known as factors that increas blood pressure and risk of cardiovascular complications. We wanted to examine effects of pentadecapeptide BPC 157 on high-fat diet induced hypertension in rats. 4 Male Winstar Albino rats (240g) 4 months old, were used in this study. 2 rats per each group were fed with fat (white bacon) for 4 weeks. Control group was given water p.o. ad libitum while BPC group was given (10ng/kg) of pentadecapeptide BPC 157 per liter solution p.o. ad libitum. Blood pressure was measured using noninvasive tail cuff method every day for 4 weeks period. Systolic blood pressure increased in both groups but increase in control groups was significantly higher then in BPC 157 threated group (CON day 0. = 158 mmHg, BPC day 0. = 155 mmHg; CON day 25. = 205 mmHg, BPC day 25. = 165 mmHg) .Drop of blood pressure in first few days can be attributed to adapting on the new food that was given to rats. Feeding rats with a high-fat diet is known to produce changes of which one of the consequence is increased blood pressure or hypertension. We proved that pentadecapeptide BPC 157 decreases systolic blood pressure induced by fat diet
    corecore